2023 / 01

Next Paper
DOI: 10.24075/brsmu.2023.006

ORIGINAL RESEARCH

Development and characterization of a vector system based on the simian adenovirus type 25

Ozharovskaia TA, Popova O, Zubkova OV, Vavilova IV, Pochtovyy AA, Shcheblyakov DV, Gushchin VA, Logunov DYu, Gintsburg AL
About authors

Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, Russia

Correspondence should be addressed: Tatiana A. Ozharovskaia
Gamalei, 18, Moscow, 123098, Russia; ur.xednay@hzo.t

About paper

Funding: the work is the result of the effort under the "Development of a recombinant vaccines platform (including live vaccines) enabling design of the infectious diseases prevention vaccines" task set by the Ministry of Health of the Russian Federation.

Acknowledgments: we express our sincere gratitude to AE Nikonova, a researcher with the Laboratory of Molecular Biotechnology of the NF Gamaleya National Research Center for Epidemiology and Microbiology for her help in conducting the phylogenetic analysis of adenovirus hexon sequences, as well as to research laboratory assistant D.D. Kustova for her help in obtaining the whole genome sequences.

Author contribution: Ozharovskaia TA, Zubkova OV, Logunov DYu, Gintsburg AL — conceptualization and planning of the experimental part; Popova O, Zubkova OV — production of genetically engineered constructs and recombinant simian adenovirus type 25; Ozharovskaia TA, Vavilova IV — phylogenetic analysis, virological experiments; Pochtovyi AA — whole genome sequencing of adenoviruses; Ozharovskaia TA, Zubkova OV — article preparation and authoring, interpretation of the results; Shcheblyakov DV, Gushchin VA — manuscript editing; Gushchin VA — state assignment project management.

Compliance with ethical standards: the work was carried out in accordance with the principles of the Declaration of Helsinki.

Received: 2022-12-29 Accepted: 2023-01-20 Published online: 2023-02-28
|
  1. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004; 10 (4): 616–29.
  2. Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther. 2015; 15 (3): 337–51.
  3. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017; 4 (2): 43–63.
  4. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol. 1994; 5 (6): 617–25.
  5. Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, et al. Virus-Vectored Ebola Vaccines. Acta Naturae. 2017; 9 (3): 4–11.
  6. Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses. 2021; 13 (2): 317.
  7. Henaff D, Salinas S, Kremer EJ. An adenovirus traffic update: From receptor engagement to the nuclear pore. Future Microbiol. 2011; 6 (2): 179–92.
  8. ICTV. The ICTV report virus taxonomy: the classification and nomenclature of viruses. 2022. Available from: https://ictv.global/taxonomy/.
  9. Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, Ndour CT, et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2020; 20 (6): 707–18.
  10. O’Hara GA, Duncan CJA, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis. 2012; 205 (5): 772–81.
  11. Younis BM, Osman M, Khalil EAG, Santoro F, Furini S, Wiggins R, et al. Safety and immunogenicity of ChAd63-KH vaccine in postkala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021; 29 (7): 2366–77.
  12. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001; 75 (23): 11603–13.
  13. Zhou D, Cun A, Li Y, Xiang Z, Ertl HCJ. A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus. Mol Ther. 2006; 14 (5): 662–72.
  14. Napolitano F, Merone R, Abbate A, Ammendola V, Horncastle E, Lanzaro F, et al. A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. PLoS Negl Trop Dis. 2020; 14 (7): e0008459.
  15. de Jong R, Stockhofe-Zurwieden N, Bonsing J, Wang KF, Vandepaer S, Bouzya B, et al. ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infectioninduced disease in young calves. Nat Commun. 2022; 13 (1): 6142.
  16. Roy S, Gao G, Lu Y, Zhou X, Lock M, Calcedo R, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther. 2004; 15 (5): 519–30.
  17. Luo S, Zhang P, Ma X, Wang Q, Lu J, Liu B, et al. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development. Virus Res. 2019; 268: 1–10.
  18. Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, et al. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol. 2010; 84 (19): 10087–101.
  19. Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, et al. Efficacy of a plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic plasmodium berghei parasites. Infect Immun. 2014; 82 (3): 1277–86.
  20. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 Gag. J Immunol. 2003; 170 (3): 1416–22.
  21. Roy S, Medina-Jaszek A, Wilson MJ, Sandhu A, Calcedo R, Lin J, et al. Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med. 2011; 13 (1): 17–25.
  22. Davis AR, Wivel NA, Palladino JL, Tao L, Wilson JM. Construction of adenoviral vectors. Mol Biotechnol. 2001; 18 (1): 63–70.
  23. Logunov DY, Zubkova OV, Karyagina-Zhulina AS, Shuvalova EA, Karpov AP, Shmarov MM, et al. Identification of HI-Like Loop in CELO adenovirus fiber for incorporation of receptor binding motifs. J Virol. 2007; 81 (18): 9641–52.
  24. Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol. 1994; 47 (3): 157–66.
  25. N Saitou, M Nei. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987; 4 (4): 406–25. DOI: 10.1093/oxfordjournals.molbev.a040454.
  26. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018; 35 (6): 1547–9.
  27. Folegatti PM, Jenkin D, Morris S, Gilbert S, Kim D, Robertson JS, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2022; 40 (35): 5248–62.
  28. Ebner K, Pinsker W, Lion T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol. 2005; 79 (20): 12635–42.
  29. Zhang W, Ehrhardt A. Getting genetic access to natural adenovirus genomes to explore vector diversity. Virus Genes. 2017; 53 (5): 675–83.
  30. Fernandes P, Silva AC, Coroadinha AS, Alves PM. Upstream bioprocess for adenovirus vectors. In: Adenoviral vectors for gene therapy. Elsevier; 2016. p. 139–61.